

Alliance for Clinical Trials in Oncology Friday, May 15, 2015 Loews Chicago O'Hare Hotel 2 pm - 5 pm

Pharmacogenomics and Population Pharmacology (PP) Committee

Chair: Mark Ratain

Vice-Chairs: Lionel Lewis and Howard McLeod

Faculty Biostatistician: Kouros Owzar

Educational Session: Dose Optimization (Mark Ratain & Joga Gobburu) 2:00-2:50

2:00-2:20	Oncology isn't different any more (Ratain)
2:20-2:40	Why regulatory agencies care (Gobburu)
2:40-2:50	Discussion

Population pharmacology (Lionel Lewis) 2:50-3:20

2:50-3:05	A model-based approach to dose optimization of neurotoxic chemotherapy for metastatic breast cancer (Mani Sharma)
3:05-3:20	Comparative effects of CT imaging measurement on RECIST endpoints and tumor growth kinetics modeling (Michael Maitland)
3.20-3.30	Break

Pharmacogenomics (Howard McLeod) 3:30-5:00

3:30-3:45	Pharmacogenomics of treatment of urothelial cancer (Helen Furberg)
3:45-4:00	Pharmacogenomics of treatment of lymphoma (Kristy Richards)
4:00-4:30	80405: Genome-wide association study of survival in metastatic colorectal cancer (Federico Innocenti)
4:30-4:45	80303: Additional analyses (Federico Innocenti)
4:45-5:00	80101: Planned analyses (Jai Patel)